Highlights from

AAN 2019

American Academy of Neurology annual meeting

Philadelphia, USA 4-10 May 2019

Cannabidiol effective in children with Dravet syndrome

Cannabidiol (CBD) in a dosage of 10 or 20 mg/kg/day significantly reduced convulsive seizure frequency in children and adolescents with Dravet syndrome (DS). This was the conclusion of GWPCARE, a dose-ranging, multicentre, randomised, double-blind, placebo-controlled trial. The higher dosage gave rise to more adverse events and discontinuations.

DS is an infantile-onset developmental and epileptic encephalopathy which is associated with drug-resistant seizures. In GWPCARE, a highly purified form of CBD was applied, which is on the market in the USA. A total of 199 children and adolescents with DS and drug-resistant seizures participated (mean age 9 years). They took a median of 3 antiepileptic drugs and had discontinued a median 4. Participants were randomised 1:1:1 to CBD 10 or 20 mg/kg/day (CBD10 or CBD20), or placebo as an add-on anticonvulsant therapy. The primary endpoint was the change in the number of convulsive seizure frequency during 14 weeks of treatment compared to a 4-week baseline.

In both active treatment groups, convulsive seizures were reduced more (CBD20: 46%, CBD10: 49%) than placebo (27%; P=0.0299 and P=0.0095). There were also significantly more patients with a ≥50% reduction in convulsive seizures, as well as a higher reduction in total seizures. The incidence of adverse events was similar across all groups: 90% CBD20, 88% CBD10, 89% placebo. However, serious AEs were reported in 25% CBD20, 20% CBD10, and 15% of placebo patients. Discontinuations due to AEs occurred only for CBD20 patients (7%). Elevated transaminases exceeding 3 times the upper limit of normal occurred in 19% CBD20 and 5% CBD10 patients; all elevations resolved. The authors concluded that any dose increase above 10 mg/kg/day should be guided by individual efficacy and safety.

Miller I, et al. AAN 2019.

The content and interpretation of these conference highlights are the views and comments of the speakers/authors.